• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CVS Health Appoints David Joyner President and Chief Executive Officer

    10/18/24 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email

    Roger Farah Named Executive Chairman of the Board

    Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10

    WOONSOCKET, R.I., Oct. 18, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced that David Joyner was appointed President and Chief Executive Officer, effective October 17, replacing Karen Lynch, who stepped down from her position in agreement with the company's Board of Directors. Joyner also joined the Board of Directors. In addition, current Chairman of the Board, Roger Farah, will now be Executive Chairman.

    CVS Health (PRNewsFoto/CVS Health)

    Joyner was most recently executive vice president, CVS Health, and president, CVS Caremark. He led the pharmacy services business, which provides solutions to employers, health plans and government entities and serves approximately 90 million members through Caremark, CVS Specialty, and other areas. 

    Joyner has 37 years of health care and pharmacy benefit management experience, and has also served on the boards of several private equity-backed health care companies. He began his career at Aetna as an employee benefit representative before joining Caremark Prescription Services as a regional sales manager. He then served as executive vice president of sales and account services at CVS Caremark and executive vice president of sales and marketing at CVS Health.

    "The Board believes this is the right time to make a change, and we are confident that David is the right person to lead our company for the benefit of all stakeholders, including customers, employees, patients, and shareholders," said Farah. "CVS Health is responsible for improving health for millions of people across the U.S., and our integrated businesses work together to deliver on our purpose and mission every day. To build on our position of strength, we believe David and his deep understanding of our integrated business can help us more directly address the challenges our industry faces, more rapidly advance the operational improvements our company requires, and fully realize the value we can uniquely create."

    "There is no greater honor than to lead a company whose mission and purpose are completely focused on improving health," said Joyner. "I came back to CVS Health in 2023 because I believed I could give more to the company, and I take this opportunity today for the same reason. I am proud to continue working side by side with our 300,000 colleagues who are building a world of health around every consumer. Every day, CVS Health expands access, drives greater affordability, and achieves better health outcomes for more than 186 million people. Aligned with our management team and our Board, I believe in the future of our company and I am committed to delivering our best every day to everyone we serve."

    Farah added: "The Board also recognizes the many contributions Karen made to our company, both during her tenure at Aetna and then as President and CEO of CVS Health. We are grateful for her consistent, customer-focused leadership, especially during the COVID-19 pandemic when our pharmacies provided needed tests and vaccines. We also appreciate her work to advance CVS Health's modernization and transformation to become a diversified, connected, technology-driven health care company, allowing us to do even more for the people we are privileged to serve."

    In connection with today's announcement, the Company is also providing preliminary guidance for third quarter 2024 GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. Results for the third quarter include charges to record premium deficiency reserves (PDRs), primarily related to the company's Medicare and Individual Exchange businesses inside its Health Care Benefits segment, of approximately $1.1 billion, which lowered third quarter 2024 Adjusted EPS by $0.63.  The PDRs are expected to be substantially released during the fourth quarter of 2024, benefiting results in that period.  The Company's GAAP results also include a restructuring charge of approximately $1.2 billion, related to incremental store closures in 2025, as well as cost reduction actions discussed on the second quarter 2024 earnings call. 

    In the third quarter of 2024, the Company has continued to experience medical cost trends in excess of those projected in its prior outlook.  The Medical Benefit Ratio ("MBR") for the third quarter is currently expected to be approximately 95.2%, which includes a 220-basis point impact from the PDRs. The Company's other segments performed consistent with prior projections in the quarter.  In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company's previous guidance provided on its second quarter 2024 earnings call on August 7, 2024.  The Company plans to further update investors on its third quarter 2024 earnings call, currently scheduled for November 6, 2024, after the company has completed its standard quarterly close processes.

    The Company's preliminary financial results are based on the Company's current estimate of its results for the quarter ended September 30, 2024, and remain subject to change based on the completion of closing and review procedures and the execution of the Company's internal control over financial reporting.

    Non-GAAP Financial Measures

    This press release includes projected Adjusted EPS, which represents a non-GAAP financial measure. The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. The most directly comparable GAAP measure is projected GAAP diluted EPS.

    Projected GAAP diluted EPS and projected Adjusted EPS, respectively, are calculated by dividing projected net income attributable to CVS Health and projected adjusted income attributable to CVS Health by the Company's projected weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, restructuring charges, office real estate optimization charges, as well as the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health.

    The following are reconciliations of projected net income attributable to CVS Health to adjusted income attributable to CVS Health and projected GAAP diluted EPS to Adjusted EPS:



    Three Months Ended September 30, 2024



    Low

    High

    In millions, except per share amounts

    Total

    Company

    Per Common

    Share

    Total

    Company

    Per Common

    Share

    Net income attributable to CVS Health (GAAP measure)

    $               40

    $              0.03

    $             103

    $            0.08

    Amortization of intangible assets

    507

    0.40

    507

    0.40

    Net realized capital gains

    (19)

    (0.02)

    (19)

    (0.02)

    Acquisition-related integration costs (1)

    41

    0.03

    41

    0.03

    Restructuring charges (2)

    1,169

    0.93

    1,169

    0.93

    Office real estate optimization charges (3)

    17

    0.01

    17

    0.01

    Tax impact of non-GAAP adjustments (4)

    (433)

    (0.33)

    (433)

    (0.33)

    Adjusted income attributable to CVS Health

    $         1,322

    $              1.05

    $         1,385

    $            1.10











    Weighted average diluted shares outstanding



    1,259



    1,259





    (1)

    During the three months ended September 30, 2024, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health.

    (2)

    During the three months ended September 30, 2024, the restructuring charges are primarily comprised of a store impairment charge, other asset impairment and related charges associated with the discontinuation of certain non-core assets, as well as corporate workforce optimization costs, including severance and employee-related costs. During the third quarter of 2024, the Company developed an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it would close 271 additional retail stores, and, accordingly, it recorded a store impairment charge to write down the associated operating lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company's best estimate of their fair value.

    (3)

    During the three months ended September 30, 2024, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company's continuous evaluation of corporate office real estate space in response to its ongoing flexible work arrangement.

    (4)

    Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

    Cautionary Statement Concerning Forward-Looking Statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, references to CVS Health's estimates for certain financial metrics for the three months ended September 30, 2024 presented in this press release, all of which are preliminary. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

    You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding preliminary financial estimates and projections, future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

    About CVS Health

    CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media. 

    Media contact

    Ethan Slavin

    860-273-6095

    [email protected]

    Investor contact

    Larry McGrath

    800-201-0938

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-appoints-david-joyner-president-and-chief-executive-officer-302280277.html

    SOURCE CVS Health

    Get the next $CVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Who has been appointed Executive Chairman of the Board at CVS Health?

      Roger Farah has been named as the Executive Chairman of the Board following the appointment of David Joyner as President and CEO.

    • What is the preliminary EPS guidance for CVS Health for the third quarter of 2024?

      CVS Health has provided preliminary guidance for third quarter 2024 GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10.

    • What is David Joyner's background and experience in the healthcare industry?

      David Joyner has extensive experience in health care and pharmacy benefit management, including roles at CVS Health and Caremark, and has a total of 37 years in the industry.

    • What financial challenges does CVS Health anticipate impacting their Adjusted EPS for the third quarter of 2024?

      The company expects charges by approximately $1.1 billion related to premium deficiency reserves (PDRs) for its Medicare and Individual Exchange businesses, which impacted Adjusted EPS by about $0.63.

    • Why did Karen Lynch step down from her position as President and CEO of CVS Health?

      Karen Lynch stepped down as President and CEO as part of the leadership changes at CVS Health, and the Board expressed gratitude for her contributions to the company.

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    10/10/2024$63.00 → $82.00Equal Weight → Overweight
    Barclays
    10/4/2024$59.00 → $85.00Hold → Buy
    TD Cowen
    5/30/2024$61.00Neutral
    Robert W. Baird
    More analyst ratings

    $CVS
    Financials

    Live finance-specific insights

    See more
    • AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

      AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A

      5/8/25 4:47:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

      First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil

      5/1/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health to hold first quarter 2025 earnings conference call

      WOONSOCKET, R.I., April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Thursday, May 1st, 2025, at 8:00 a.m. ET to discuss first quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2024, th

      4/3/25 9:00:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CVS Health Corporation

      SC 13G - CVS HEALTH Corp (0000064803) (Subject)

      11/13/24 1:00:57 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

      SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

      2/13/24 5:02:40 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

      SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

      2/9/23 11:16:32 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      2/19/25 12:35:35 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Ludwig Edward J bought $53,879 worth of shares (1,000 units at $53.88), increasing direct ownership by 5% to 21,630 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/2/24 4:31:44 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahoney Michael F bought $500,294 worth of shares (9,181 units at $54.49), increasing direct ownership by 5,246% to 9,356 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/2/24 4:30:49 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robbins Larry sold $253,695,413 worth of shares (3,750,000 units at $67.65) (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      5/6/25 4:15:27 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP and Group President Shah Prem S covered exercise/tax liability with 1,308 shares and was granted 26,478 shares, increasing direct ownership by 20% to 58,166 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      4/3/25 4:43:05 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP and President, Aetna Nelson Steven H was granted 21,329 shares (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      4/3/25 4:29:13 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    SEC Filings

    See more
    • SEC Form 13F-HR filed by CVS Health Corporation

      13F-HR - CVS HEALTH Corp (0000064803) (Filer)

      5/2/25 4:08:15 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 10-Q filed by CVS Health Corporation

      10-Q - CVS HEALTH Corp (0000064803) (Filer)

      5/1/25 6:35:46 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CVS HEALTH Corp (0000064803) (Filer)

      5/1/25 6:32:09 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CVS
    Leadership Updates

    Live Leadership Updates

    See more

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

      AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A

      5/8/25 4:47:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Glenview Capital Issues Statement on CVS Health

      NEW YORK, May 6, 2025 /PRNewswire/ -- One year ago, we established a concentrated position in shares of CVS Health (NYSE:CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company.  Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan: Board Refreshment – The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.  The entire Board is operating cooperat

      5/6/25 4:15:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

      First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil

      5/1/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

      WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

      4/8/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

      Foundation announces $2 million in new Health Zones funding to support at-risk populations WOONSOCKET, R.I., March 6, 2025 /PRNewswire/ -- The CVS Health® Foundation today announced $2 million in new Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its agency partners, all located in Hartford, Connecticut. This funding will help address critical gaps in the health care and social system for individuals with chronic health conditions by increasing access to comprehensive health care services and resources. "A variety of interconnected fac

      3/6/25 8:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health announces Pharmacy and Consumer Wellness leadership appointments

      WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new

      12/3/24 7:00:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously

      2/13/25 7:04:02 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded CVS Health from Neutral to Overweight

      2/12/25 2:18:18 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • CVS Health upgraded by Edward Jones

      Edward Jones upgraded CVS Health from Hold to Buy

      1/30/25 7:09:02 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples